hims stock is being pulled into a debate that is less about one company’s next product and more about where U. S. health policy may be headed. One prominent line of commentary argues Hims & Hers Health is “leaving GLP-1s behind, ” after a steep share decline since an earlier coverage point. At the same time, Health and Human Services Secretary Robert F. Kennedy Jr. has publicly discussed loosening restrictions on a subset of peptides affected by a prior FDA move aimed at compounding pharmacies—an issue that keeps regulatory uncertainty in focus.
Why Hims Stock Is Being Read Through a Regulatory Lens
Two threads are intersecting in market attention. First, there is an investor narrative emphasizing that the market has been overly fixated on GLP-1s while “almost ignoring opportunities coming from other” areas of the business. That view is paired with the observation that the stock has fallen 58% since the author’s first coverage of Hims & Hers Health in January. Those facts do not, on their own, explain the next move in hims stock, but they frame why investors are scrutinizing what comes after peak GLP-1 excitement.
Second, U. S. health regulators are again at the center of the conversation—this time through the lens of peptides and compounding. RFK Jr. said on a major podcast that he intends to reverse a previous decision from the Biden-era FDA that restricted nearly two dozen peptides from being produced by compounding pharmacies. The FDA is expected to consider taking around 14 peptides off the banned list, with a formal decision expected in the next few weeks. The timeline matters because it compresses uncertainty into a narrow window, increasing the likelihood that sentiment around health-related platforms and adjacent markets could shift quickly.
For hims stock specifically, the relevance is indirect but real: when policy signals suggest a softer stance on certain unapproved compounds, it can change how investors think about the broader ecosystem of wellness demand, gray-market supply, and the boundaries between approved therapies and loosely regulated alternatives. That ecosystem can influence consumer behavior, competitive intensity, and political scrutiny—without any single company needing to be explicitly named in the policy action.
Peptides, Compounding, and the Policy Shift That Could Move Sentiment
RFK Jr. described plans to loosen restrictions on certain popular, “albeit unapproved, ” drugs. He referenced the FDA’s earlier restriction of nearly two dozen peptides from being produced by compounding pharmacies, adding that the FDA will consider removing roughly 14 from the banned list. Importantly, he also acknowledged that evidence supporting their use “hasn’t been fully gathered, ” while expressing hope that access would come from “ethical suppliers. ”
The underlying regulatory story is not new. In September 2023, the FDA made sweeping changes to its bulk drug substances list for compounding, placing 19 peptides on the Category 2 list—meaning pharmacies could no longer produce these compounds legally. The agency also flagged other peptides not on the list for potential concerns. RFK Jr. argued the FDA banned the peptides because they were not proven effective, rather than necessarily unsafe. Yet the FDA has cited safety risks, including awareness of adverse events and deaths linked to growth hormone-releasing peptide-2 (GHRP-2). For other peptides, the agency determined there was little to no “data in humans to inform safety-related considerations. ”
For investors tracking hims stock, the key is not whether peptides become the next headline product category, but how fast the regulatory perimeter can move—and what that implies about enforcement appetite, risk tolerance, and the political optics of “access” versus “evidence. ” A faster policy pendulum can amplify volatility in any health-adjacent equity where the market narrative leans on consumer demand and convenience.
There is also an active legal and industry dimension. Compounding pharmacy trade groups and others have accused the FDA of overreaching in its bans, and lawsuits have argued some peptides have shown enough promise to merit continued access. Even without predicting outcomes, the existence of organized pushback signals that compounding policy will remain contested, which typically increases headline risk.
The Deeper Read: A GLP-1 Hangover Meets a “Gray Market” Spotlight
Analysis: the most consequential element may be the combination of a post-GLP-1 narrative reset and an emerging spotlight on unapproved wellness compounds. The peptide landscape described here includes influencer-driven demand for anti-aging, brain health, and weight loss, alongside early-stage or unapproved drugs circulating in a gray market. That is not a stable environment for long-duration confidence; it tends to generate cycles of hype, backlash, enforcement, and legal dispute.
At the company level, the “leaving GLP-1s behind” framing suggests a strategic communication challenge: convincing investors that the next leg of growth does not depend on a single drug category dominating attention. At the market level, the peptide discussion suggests a policy challenge: regulators balancing access, safety, and evidence when consumer demand is already ahead of clinical consensus.
Facts: the only quantified performance marker in the provided context is the 58% decline from the author’s January coverage point. That decline does not assign blame to a single catalyst. But it does explain why new regulatory headlines—especially those with a decision expected “in the next few weeks”—can disproportionately affect sentiment around hims stock, which is already being interpreted through a transition story.
Expert perspectives in this specific update are limited to public statements and institutional positions. Robert F. Kennedy Jr., U. S. Secretary of Health and Human Services, stated he would soon loosen restrictions on certain unapproved peptides and that evidence supporting their use has not been fully gathered. The U. S. Food and Drug Administration has maintained that it is aware of safety risks for some peptides and that, for others, human safety data are limited.
Globally and regionally, the immediate impact is U. S. -centric, because the FDA’s compounding framework and bulk substances categorization shape domestic production legality. Still, U. S. regulatory posture often influences how international investors price risk in consumer-health business models. A perceived softening can encourage demand narratives; a renewed safety-focused stance can elevate compliance and reputational risk narratives. Either shift can reverberate through market conversations about hims stock.
The next inflection point is procedural and near-term: if a formal FDA decision on roughly 14 peptides arrives within weeks, the policy tone will become clearer. For investors watching hims stock, the enduring question is whether the market can separate a company’s post-GLP-1 identity from a broader, politically charged argument over what “access” should mean when evidence is still incomplete.
